HRMY
NASDAQHarmony Biosciences Holdings Inc.
Price$38.94+0.22 (+0.57%)
01:45 PM07:45 PM
News · 26 weeks480%
2026-03-012026-08-23
Mix1890d
- SEC Filings10(56%)
- Other5(28%)
- Earnings2(11%)
- Insider1(6%)
Latest news
25 items- PRHarmony Biosciences to Participate in Piper Sandler Virtual CNS SymposiumPLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitme
- SECSEC Form 10-Q filed by Harmony Biosciences Holdings Inc.10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class ProfileWAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027 Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Dat
- INSIDERNew insider Mollichella Stephen M. claimed ownership of 2,506 shares (SEC Form 3)3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- PRHarmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybi
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO TransitionWAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentu
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- PRParagon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva PharmaceuticalAgreement highlights Paragon's ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them. Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmony Biosciences (NASDAQ:HRMY). Ecopipam, an investigati
- PRHarmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual MeetingHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with Narcolepsy: Pooled Analysis of Two Randomized Clinical Trials P-16 (Poster #387), 6/15/2026, 10:00-10:45 a.m. Effect of Pitolisant on Sleep Patterns in Idiopathic Hypersomnia: Analysis of Phase 3 Trial Sleep
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- PRHarmony Biosciences to Participate in Upcoming Investor ConferencesHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for
- INSIDERSEC Form 4 filed by Director Germano Geno J4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 3 filed by new insider Germano Geno J3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Szyper Linda M4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf R. Mark4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Sabater Juan A.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Sender Gary4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
HRMY FAQ
7 questionsWhat does Harmony Biosciences Holdings Inc. do?
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.Where does HRMY stock trade?
Harmony Biosciences Holdings Inc. (HRMY) is listed on NASDAQ.What sector and industry is HRMY in?
Harmony Biosciences Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Harmony Biosciences Holdings Inc. go public?
Harmony Biosciences Holdings Inc. (HRMY) completed its IPO in 2020.What are analysts saying about HRMY?
Harmony Biosciences Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Hold on 2026-02-23. Recent price targets range from $3300.00 to $4800.00.What companies are similar to HRMY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HRMY side-by-side with any of them on Quantisnow.How can I track HRMY on Quantisnow?
Quantisnow aggregates Harmony Biosciences Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HRMY to receive live email and push alerts on every new disclosure.